SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
SEC Accession No. 0001072613-22-000649
Filing Date
2022-11-28
Accepted
2022-11-28 15:19:35
Documents
1
Group Members
ANTHONY A. FLORENCE, JR.FOREST BASKETTMOHAMAD H. MAKHZOUMINEA 15 GP, LLCNEA PARTNERS 15, L.P.NEW ENTERPRISE ASSOCIATES 15, L.P.PETER W. SONSINISCOTT D. SANDELL

Document Format Files

Seq Description Document Type Size
1 GROWTH EQUITY OPPORTUNITIES FUND IV (ADDEX THERAPEUTICS) - SCHEDULE 13D/A3 geoiv-addex_18679.htm SC 13D/A 333523
  Complete submission text file 0001072613-22-000649.txt   335426
Mailing Address CHEMIN DES MINES 9 GENEVA V8 CH-1202
Business Address CHEMIN DES MINES 9 GENEVA V8 CH-1202 01141228841555
Addex Therapeutics Ltd. (Subject) CIK: 0001574232 (see all company filings)

IRS No.: 000000000 | State of Incorp.: V8 | Fiscal Year End: 1231
Type: SC 13D/A | Act: 34 | File No.: 005-91805 | Film No.: 221424906
SIC: 2834 Pharmaceutical Preparations

Mailing Address 1954 GREENSPRING DRIVE SUITE 600 TIMONIUM MD 21093
Business Address 1954 GREENSPRING DRIVE SUITE 600 TIMONIUM MD 21093 410-842-4000
Growth Equity Opportunities Fund IV, LLC (Filed by) CIK: 0001644965 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A